Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342795 · ClinicalTrials.gov registry record · Phase 1
Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation
A Phase 1 study of Nontherapeutic, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 520
- Enrollment target
- 2
- Study locations
NCT02342795 is a Phase 1 study of Nontherapeutic that has completed, run by Virginia Commonwealth University. The registered enrollment target is 520 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02342795, a Phase 1 study of Nontherapeutic, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 520 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to use Randomized Controlled Trial (RCT) methods to examine the influence of novel tobacco products on biomarkers of toxicant exposure and disease risk, reports of adverse events, and concurrent use of other tobacco products. In this case, the novel products are one type of electronic cigarette and an imitation cigarette or cigarette substitute.
Conditions Studied
Interventions
- OTHER e-cigarette
- OTHER cigarette substitute
Study Locations (2)
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Virginia
- Center for the Study of Tobacco Products - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02342795
The ClinicalTrials.gov registry entry for NCT02342795 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nontherapeutic appearing as the primary indexed condition, and to 2 interventions - of which e-cigarette is the first listed.
NCT02342795 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT02342795 about?
NCT02342795 is a clinical study titled "Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation". The purpose of this study is to use Randomized Controlled Trial (RCT) methods to examine the influence of novel tobacco products on biomarkers of toxicant exposure and disease risk, reports of adverse events, and concurrent use of other tobacco products. In this case, the novel products are one type...
What is the current status of trial NCT02342795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 520 participants. The study started on 2015-06. Estimated completion is 2018-07.
What conditions does trial NCT02342795 study?
This clinical trial studies the following conditions: Nontherapeutic.
What interventions are being tested in trial NCT02342795?
The interventions under investigation include: e-cigarette (OTHER), cigarette substitute (OTHER).
Who is sponsoring clinical trial NCT02342795?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02342795 being conducted?
This trial has 2 study locations across Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.